February 19, 2021
Ono Pharmaceutical said on February 18 that it has submitted an application in Japan for its anti-PD-1 antibody Opdivo (nivolumab), seeking an additional indication of postoperative adjuvant therapy for resected esophageal cancer. The submission rides on the back of data...read more